QUENTIN-FROIGNANT, Charlotte; TOLLEFSON, Ann E; CLINE-SMITH, Anna; KAPPLER-GRATIAS, Sandrine; LANDREIN, Nicolas; ROY, Vincent; AGROFOGLIO, Luigi A; TOTH, Karoly; WODRICH, Harald; GALLARDO, Franck

doi:10.1021/acsinfecdis.5c00170

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

QUENTIN-FROIGNANT, Charlotte

TOLLEFSON, Ann E

CLINE-SMITH, Anna

Langue

Article de revue

Ce document a été publié dans

ACS Infectious Diseases. 2025-05-19

Résumé en anglais

Adenoviruses are responsible for a range of pathologies, including respiratory infections in children. Although most adenovirus infections are self-resolving, they can cause serious illness, particularly in immunocompromised individuals. There is currently no approved treatment for adenovirus infections. Here, we report on the antiviral activity of LAVR-289, a broad-spectrum acyclonucleoside phosphonate exhibiting potent efficacy against several adenovirus serotypes, comparable to that of brincidofovir. LAVR-289 specifically inhibits viral replication, blocking the formation of viral replication centers and preventing late protein expression without affecting viral entry or delivery of viral genomes to the nucleus. , using immunocompromised Syrian hamsters infected with HAdV-C6, oral administration of LAVR-289 resulted in 100% animal survival. These results suggest that LAVR-289 holds promise as a potential therapy for adenovirus infections paving the way for a future treatment of immunocompromised patients.< Réduire

Mots clés en anglais

Acyclic nucleoside phosphonate prodrug; Adenovirus infection; Antiviral; LAVR-289; in vivo

Métadonnées

Partager cette publication !

Licence d’utilisation du document

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche